Last Updated : September 8, 2023
Details
FilesGeneric Name:
abiraterone, prednisone, docetaxel
Project Status:
Complete
Therapeutic Area:
Metastatic castration sensitive prostate cancer (mCSPC)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0298-000 - PC0298-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
For the treatment of metastatic castration sensitive prostate cancer in combination with androgen deprivation therapy.
Recommendation Type:
Reimburse
Final Recommendation:
| Call for patient/clinician input open | 07-Jul-22 |
|---|---|
| Call for patient/clinician input closed | 26-Aug-22 |
| Clarification: - Patient input submission received from the Canadian Cancer Society | |
| Call for industry input open | 07-Jul-22 |
| Call for industry input closed | 26-Aug-22 |
| Review initiated | 06-Sep-22 |
| Expert committee meeting (initial) | 29-Jun-23 |
| Draft recommendation posted for stakeholder feedback | 20-Jul-23 |
| End of feedback period | 03-Aug-23 |
| Final recommendation posted | 08-Sep-23 |
| CADTH review report(s) posted | 08-Sep-23 |
Files
Last Updated : September 8, 2023